Advertisement
Screener

10x Genomics, Inc. (TXG) Current Ratio

10x Genomics, Inc. (TXG) Current Ratio

  • Current ratio · latest quarter: Value 5.69×; Formula and calculation Current assets / current liabilities..

Current ratio

Overview →

Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.

MetricValueFormula and calculation
Current ratio · latest quarter5.69×Current assets / current liabilities.

$674.67M ÷ $118.51M ≈ 5.69×

Calculation inputs

InputAmount with unitRaw financial data
Current assets674.67M USDAssets, Current
Current obligations118.51M USDLiabilities, Current
Cash and equivalents(m)Cash and Cash Equivalents, at Carrying Value
Short-term securities49.52M USDDebt Securities, Available-for-sale, Current
Customer receivables47.55M USDAccounts Receivable, after Allowance for Credit Loss, Current
Inventory52.62M USDInventory, Net
Payables20.69M USDAccounts Payable, Current
Borrowing debt due within one year(m)Long-term Debt, Current Maturities

Calculated history

Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.

Period endingCurrent assets (USD)Current obligations (USD)Cash and equivalents (USD)Short-term securities (USD)Customer receivables (USD)Inventory (USD)Payables (USD)Borrowing debt due within one year (USD)Current ratio
2026-06-30$674.67M$118.51M(m)$49.52M$47.55M$52.62M$20.69M(m)5.69×
2026-03-31$669.73M$113.60M(m)$49.56M$39.03M$53.49M$17.43M(m)5.90×
2025-12-31$684.45M$153.45M(m)$49.44M$47.01M$56.34M$12.73M(m)4.46×
2025-09-30$659.83M$147.32M(m)$49.58M$43.78M$61.96M$18.07M(m)4.48×
2025-06-30$655.66M$112.22M(m)$49.55M$49.98M$68.97M$15.94M(m)5.84×
2025-03-31$579.73M$107.90M(m)$49.84M$52.55M$74.71M$10.07M(m)5.37×
2024-12-31$584.39M$117.63M(m)$49.34M$87.86M$83.11M$12.91M(m)4.97×
2024-09-30$593.89M$121.23M(m)$0.00$83.53M$94.05M$26.21M(m)4.90×
2024-06-30$579.15M$111.02M(m)$269.00K$91.18M$88.27M$21.25M(m)5.22×
2024-03-31$567.09M$108.73M(m)$16.03M$91.31M$83.19M$20.22M(m)5.22×
2023-12-31$596.02M$127.16M$359.28M$29.41M$114.83M$73.71M$15.74M(m)4.69×
2023-09-30$562.35M$104.72M(m)$45.64M$103.85M$80.92M$18.84M(m)5.37×
2023-06-30$582.94M$98.09M(m)$65.51M$87.69M$83.69M$23.12M(m)5.94×
2023-03-31$601.89M$112.01M(m)$85.97M$77.94M$82.31M$29.32M(m)5.37×
2022-12-31$635.03M$130.96M$219.75M$210.24M$104.21M$81.63M$21.60M(m)4.85×
2022-09-30$629.42M$126.86M(m)$218.44M$83.55M$78.63M$21.59M(m)4.96×
2022-06-30$666.23M$117.91M(m)$225.55M$76.20M$70.65M$26.73M(m)5.65×
2022-03-31$697.34M$94.45M(m)$226.84M$76.53M$63.70M$18.96M(m)7.38×
2021-12-31$747.59M$110.36M$587.45M$0.00$85.25M$59.97M$17.35M(m)6.77×
2021-09-30$744.10M$100.38M(m)(m)$78.43M$51.14M$17.04M(m)7.41×
2021-06-30$757.17M$113.13M(m)(m)$59.68M$44.09M$16.18M(m)6.69×
2021-03-31$745.72M$120.55M(m)(m)$57.41M$38.51M$15.58M(m)6.19×
2020-12-31$774.37M$118.13M$663.60M(m)$51.21M$29.96M$4.71M(m)6.56×
2020-09-30$900.45M$145.57M(m)(m)$36.03M$25.12M$9.49M$0.006.19×
2020-06-30$451.58M$122.18M(m)(m)$22.73M$21.76M$9.92M$0.003.70×
2020-03-31$429.73M$59.07M(m)(m)$30.85M$19.36M$13.51M(m)7.28×
2019-12-31$480.84M$63.05M$424.17M(m)$33.37M$15.27M$13.03M$9.88M7.63×
2019-09-30$474.14M$48.24M$427.44M(m)$26.15M$13.30M$11.96M$7.38M9.83×
2018-12-31$106.24M$32.36M$65.08M(m)$28.09M$8.57M$8.79M$4.19M3.28×

(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.